Teva price target raised to $14 from $13 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Teva to $14 from $13 and keeps a Buy rating on the shares. The firm e believes based on its review of Teva’s U.S. generics segment that the company can achieve low single-digit growth, even excluding contributions from the “two wildcards” of Korlym and Humira-IC, the analyst tells investors. The high single-digit base business erosion headwind should be more than offset by Gx Sandostatin LAR launch and incremental generic Revlimid sales, the analyst contends.